CSIMarket Company Name, Ticker, Customers, else..
 
Bridgebio Pharma Inc   (NASDAQ: BBIO)
 
Price: $72.3800 $-0.12 -0.166%
Day's High: $74.1050033569336 Week Perf: -3.29 %
Day's Low: $ 72.26 30 Day Perf: -13.67 %
Volume (M): 255,591 52 Wk High: $ 93.42
Volume (M$): $ 0 52 Wk Avg: $70.76
Open: $73.22 52 Wk Low: $48.78



 Market Capitalization (Millions $) 14,171
 Shares Outstanding (Millions) 196
 Employees 839
 Revenues (TTM) (Millions $) 713
 Net Income (TTM) (Millions $) -702
 Cash Flow (TTM) (Millions $) 131
 Capital Exp. (TTM) (Millions $) 3

Business Description


BridgeBio Pharma Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing targeted therapies to treat genetic diseases. The company utilizes a diversified approach to drug development, targeting a range of diseases including oncology, cardiology, dermatology, neurology, and endocrinology. BridgeBio operates through a subsidiary model, with a portfolio of subsidiaries that are controlled by the company and dedicated to specific genetic diseases. The company aims to apply innovative science to address the unmet needs of patients with genetic diseases and bring transformative therapies to market.


   Company Address: 3160 Porter Drive Palo Alto 94304 CA
   Company Phone Number: 391-9740   Stock Exchange / Ticker: NASDAQ BBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ONC   -4.87%    
PFE   -4.46%    
RCUS   -16.64%    
TEVA   -1.47%    
VRTX   -8.07%    
VTRS   -2.95%    
• View Complete Report
   



Clinical Study

BridgeBio Pharmas Pivotal Moment Unveiling Phase 3 Results of Encaleret for ADH1,

Published Wed, Oct 29 2025 4:50 PM UTC

: BridgeBio Pharma, Inc. is set to reveal the Phase 3 results of their promising candidate, Encaleret, for treating autosomal dominant hypocalcemia type 1 (ADH1). As the anticipation builds, the pharmaceutical industry is keenly observing the company s financial trajectory, which combines staggering revenue growth with ongoing net losses. Through this article, we explore the...
Clinical Study

Efficacy of Encaleret in Autosomal Dominant Hypocalcemia Type 1 Positive Outcomes from the CALIBRATE Phase 3 Study

Published Wed, Oct 29 2025 1:41 PM UTC

: The management of Autosomal Dominant Hypocalcemia Type 1 (ADH1), a rare genetic disorder characterized by hypoparathyroidism and associated calcium and magnesium imbalances, has been challenging. Recent developments in pharmacotherapy have offered new hope for affected patients. This article summarizes the positive results of the CALIBRATE Phase 3 clinical trial assessing ...
Clinical Study

BridgeBios Acoramidis Promising Outcomes in ATTR-CM at HFSA 2025

Published Mon, Sep 22 2025 11:51 AM UTC

In the ever-evolving landscape of biopharmaceuticals targeting genetic diseases, BridgeBio Pharma, Inc. stands out as a company committed to advancing treatment options for conditions associated with transthyretin (TTR) amyloidosis, specifically transthyretin amyloid cardiomyopathy (ATTR-CM). With the impending 2025 Heart Failure Society of America (HFSA) Annual Scientific ...
Product Service News

In a significant move to bolster its workforce and fuel its mission to combat genetic diseases, BridgeBio P...

Published Wed, Sep 10 2025 8:08 PM UTC

BridgeBio Pharma Elevates Talent Acquisition with Inducement Grants Amidst Unprecedented Revenue Growth In a significant move to bolster its workforce and fuel its mission to combat genetic diseases, BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the approval of inducement equity grants to new employees. This decision comes at a moment when the company is demonstrating rema...
Clinical Study

Bridging the Calcium Gap Encalerets Promise in Post-Surgical Hypoparathyroidism

Published Mon, Sep 8 2025 8:42 AM UTC

Hypoparathyroidism, particularly following surgical interventions, presents a significant challenge in managing calcium homeostasis in patients. Traditional therapies often fail to achieve appropriate normalization of blood and urine calcium levels, leading to a cascade of metabolic complications. Recently, a Phase 2 proof-of-concept study has shone a spotlight on encale...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 19.87
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.81
Working Capital Ratio 1.23
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.58 $
Revenues (TTM) 3.64 $
Cash Flow (TTM) 0.67 $
Cash 3.68 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 849,903
Net Income per Employee (TTM) -836,732
Receivable Turnover Ratio (TTM) 3.99
Inventory Turnover Ratio (TTM) 1.16
Asset Turnover Ratio (TTM) 0.63

Profitability Ratios Current
Gross Margin (MRQ) 93.83 %
Operating Margin (MRQ) -43.94 %
Net Margin (MRQ) -63.97 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Bridgebio Pharma Inc's Segments
Product    165.4 % of total Revenue
License and Service    1.27 % of total Revenue
Royalty    10.23 % of total Revenue
Reportable    179.83 % of total Revenue
License, Services and Royalty    11.45 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.